The World Leading Cancer Gene Therapy Company

PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.

We focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using our proprietary intravenously administered T-SIGn virus platform. Our portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumor.

At PsiOxus we are advancing our internal early and clinical stage candidates and establishing strategic partnerships with immuno-oncology leaders to bring our cancer gene therapy products to patients.

Enadenotucirev

An optimised oncolytic virus

T-SIGn

Tumour-Specific Immuno-Gene Therapy Platform

NG-348

The first next generation T-SIGn virus

NG-347

Click for more info

NG-350A

More info available soon

NG-aFAP

More info available soon

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image
Menu